Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. by Kakeji, Y. et al.
Br. J. Cancer (1993), 67, 589 593 © Macmillan Press Ltd.,
Gastric cancer with p53 overexpression has high potential for
metastasising to lymph nodes
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Summary Overexpression of the tumour suppressor gene p53 was investigated immunohistochemically in 96
primary gastric carcinomas and 26 corresponding metastatic perigastric lymph nodes. Abnormalities in p53
expression were found in 52 (54%) of the 96 primary carcinomas. Tumours stained positively for p53
frequently metastasised to lymph nodes (the metastatic rate: 85%) compared to findings in those with negative
p53 staining (64%, P<0.05). Ninety-two percent (24/26) of the malignant cells in the lymph nodes stained
positively for p53. When the DNA ploidy pattern of the tumour was determined by flow cytometry, the
aneuploid tumours in p53 positive and negative groups accounted for 69% and 45%, respectively (P<0.05).
Proliferative activity of the tumour, as measured by Ki-67 labelling, was significantly higher (30.6± 12.0%) in
the p53 positive group than that (25.1 ± 10.7%) in the p53 negative group (P<0.05). Thus, gastric cancer with
a mutant p53 has high proliferative activity and metastasis to lymph nodes will probably occur.
Cancer occurs when there are multiple mutations in genes
(Cairns, 1981; Bishop, 1987). Some classes of genes normally
function to prevent or suppress tumourigenesis and inactiva-
tion of such genes leads to an oncogenic state (Hollingsworth
& Lee, 1991). The p53 gene is one of these 'tumour suppres-
sor genes', and p53 is a 53 kD nuclear protein which seems
to regulate entry into the progression through the normal cell
cycle (Mercer et al., 1984). Studies of p53 expression in
cultured cells suggested that increased levels are associated
either with an abnormal mutated protein (Finlay et al.,
1988), or with stabilisation of the protein in a complex with
viral antigens, e.g. SV40 large T antigen (Lane & Crawford,
1979). Mutation of the p53 gene at a highly conserved
sequence and alteration in the expression of p53 protein are
frequent occurrences in human malignancies (Nigro et al.,
1989; Bartek et al., 1990; Rodrigues et al., 1990; Iggo et al.,
1990).
There are basic data on p53 gene alterations in specimens
of gastric cancer (Tamura et al., 1991; Kim et al., 1991;
Yamada et al., 1991). We examined the content of mutant
p53 protein immunohistochemically using a large number of
clinical samples, and associations with clinicopathological
features were analysed. To clarify characteristics of the p53
positive tumour cells, we also analysed DNA ploidy patterns
and cell proliferative activity determined by Ki-67 (Gerdes et
al., 1983) staining, a monoclonal antibody that recognises a
human nuclear antigen expressed by proliferating cells.
Materials and methods
Patients
This study included 96 unselected patients with primary gas-
tric cancer, all of whom underwent gastrectomy with lymph
node dissection in the Department of Surgery II in Kyushu
University Hospital and affiliated hospitals in Fukuoka,
Japan, from 1989 to 1990. No patient had been treated
preoperatively with cytotoxic drugs. Histology of excised tis-
sues were examined in hematoxylin and eosin (H&E) stained
preparations and classification was made according to the
criteria of the Japanese Research Society for Gastric Cancer
(1981).
Tissue samples
We sampled both the deep periphery of the tumour and
adjacent uninvolved tissue, and from each case one represen-
tative large perigastric lymph node was sampled. Of all 96
cases, 26 metastatic lymph nodes could be investigated for
p53 staining. Tissue samples for p53 and Ki-67 staining from
96 primary tumours and 26 metastatic lymph.nodes were
fixed in periodate-lysine-paraformaldehyde (PLP) for 5 h
immediately after surgical resection, embedded in OCT com-
pound (Miles, Elkhart) and preserved at - 80'C. Six ftm
sections were cut on cryostat. For DNA ploidy analysis,
samples taken from the same specimen used for histological
staining were used fresh or were frozen without fixation at
- 80°C and used within 48 h.
Immunohistochemical staining ofp53 and Ki-67
PAb24O (Gannon et al., 1990) is a mouse monoclonal anti-
body that recognises an evolutionarily conserved epitope on
p53, the epitope lies between amino acids 156 and 214 on
murine p53. This antibody reacted with human, mouse, rat,
hamster, bovine and chicken p53 in Western immunoblotting
experiments (Gannon et al., 1990). The avidin-biotin-peroxi-
dase complex (ABC) method was used for staining. Sections
were first washed in phosphate-buffered saline, pH 7.2 (PBS),
and then incubated at room temperature with normal horse
serum (Vector Laboratories, Burlingame, CA: 1:10 for 15
min). We then added PAb24O (Oncogene Science, New York:
1:50 overnight), biotinylated horse anti-mouse IgG (Vector
Laboratories, Burlingame CA: 1:200 for 30 min), Avidin-
biotin-peroxidase complex (Vector Laboratories: for 30 min).
Peroxidase labelling was developed with a diaminobenzidine
(DAB) and hydrogen peroxidase (H202), and the sections
were counterstained with Mayer's hematoxylin. We used
KUPL40 (Shirasawa et al., 1991) as the positive control, a
carcinoma from a patient with familial polyposis coli trans-
planted into nude mice and known to contain a mutation in
the p53 gene, detected by sequencing. Omission of the
primary antibody served as the negative control.
To measure the proliferative activity, we used mouse
monoclonal Ki-67 antibody (Dako, Copenhagen, Denmark:
1:100 overnight), then the procedures described above and
the ABC method. We examined 1,000 nuclei in areas of the
section with the highest labelling rates.
Flow cytometric analysis ofthe DNA ploidy pattern
Preparation of cell suspensions and measurement of nuclear
fluorescence were done as described by Sasaki et al. (1991).
Cellular DNA content was measured using a FACscan flow
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cytometer (Becton-Dickinson Immunocytometry Systems,
Mountain View, CA). The fluorescent signals from 10,000
cells were collected and the results displayed in the form of a
frequency distribution histogram (DNA histogram). A dip-
loid pattern of the tumour cells was defined as a single GO/GI
peak on the DNA histogram and an aneuploid pattern as at
least one other clearly distinct GO/GI peak followed by a
small G2+M peak. The DNA index (DI) was defined as the
ratio of the peak channel number of the GO/GI tumour
population divided by the peak channel number of GO/GI
diploid reference population. Data with a coefficient of varia-
tion (C.V.) over 8% and/or with excessive debris were exc-
luded from study. The mean C.V. was 4.28 ± 1.82%.
Statistical analysis
Clinicopathological data was stored in an IBM 4381 main-
frame computer. The Biomedical Computer Program (BMDP)
was used for all statistical analyses (Dixon, 1988). The in-
formation used included the sex, age, tumour location and
size, gross appearance according to the Borrman classifi-
cation, degree of gastric wall invasion, status of lymph node
metastatsis, and pathological class. The BMDP P4F and P3S
programs were used for the chi-square test and the Mann-
Whitney test to compare characteristics between p53 positive
and negative groups. Quantitative data on the DNA index
and Ki-67 proliferative activity were compared using Student's
t test.
Results
p53 and clinicopathologicalfeatures
We stained both the deep periphery of the tumour and
adjacent tumour-free tissue. A distinct nuclear immunoreac-
tion for p53 was judged as positive. In the positive cells, the
a
b
Figure 1 a, Photomicrograph of primary gastric cancer as seen in a frozen section stained using monoclonal antibody PAb240.
Note the homogenous, positive nuclear staining ( x 100). b, Metastatic cancer in a perigastric lymph node. There is a wide-spread
overexpression of p53 yet there was no detectable expression of p53 in the primary tumour ( x 100).p53 AND L.N. METASTASIS IN GASTRIC CANCER 591
nuclear staining pattern was diffuse with little variation
(Figure la). Cytoplasmic staining was seen in a few cases but
the intensity was weak. Heterogeneity of p53 staining in one
specimen of each case was recognised in 9 (9.4%) cases.
Though almost all positive cells formed clusters, for only one
case was there sporadic staining (1%) of cancer cells and here
there was no vessel invasion or lymph node metastasis. Sam-
ples in wich rare nuclei exhibited positive staining for p53 or
samples with weak reactivity were considered to express nor-
mal levels of p53 (Davidoff et al., 1991a,b; Isola et al., 1992;
Hiyoshi et al., 1992). Case with over 10% cancer cells show-
ing positive nuclear staining were defined as 'positive-
staining'. Positive p53 staining was evident in 52 (54%) of 96
primary gastric tumours. The surrounding gastric tissue with
no histological evidence of malignant invasion did not stain.
Table I shows clinicopathologic characteristics and p53
overexpression. There was no obvious relation between p53
staining and the sex or age of the patient. Association with
histologic type was not statistically significant, though cancer
cells with a tubular or medullary formation often stained
positive for p53. Some early stage gastric cancers stained
positively for p53, the staining being similar in proportion to
tumours showing invasion into deeper layers. However, a
significant association was found between p53 overexpression
and the metastatic spread to lymph nodes. p53-positive
tumours were associated with a higher incidence of metas-
tasis to lymph nodes (85%) than were p53-negative (64%,
P<0.05). A p53-positive gastric cancer correlated with a
higher rate of venous invasion (88%), compared with the
p53-negative isolates (68%, P<0.05). As for metastasis to
the liver, and peritoneal dissemination, there were no statis-
tical differences.
We also investigated 26 metastatic lymph nodes using
PAb240 (Table II). The majority of the cancer cells in the
metastatic lymph nodes stained positively for p53. In 17 of
18 cases with a p53-positive primary and in 7 of 8 with a p53
negative primary tumour, the metastatic nodes stained posi-
tively for p53 (Figure lb).
As for the prognosis, the follow-up period was only 1-3
years, however, at this writing we found no significant diffe-
rences between p53-positive and negative groups (data not
shown).
p53 and DNA ploidy orproliferative activity
p53-positive isolates showed a significantly higher incidence
of aneuploid pattern (69%) than did p53-negative isolates
(45%, P<0.05, Table III). The mean DNA index for the
Table I p53 overexpression and clinicopathological characteristics
p53 staining
Negative Positive
n(%) n(%) P value
1 Sex
Men 31 (70) 33 (63) N.S.a
Women 13 (30) 19 (37)
2 Age, y (mean±s.d.) 64.1± 10.8 62.4± 12.0 N.S.
3 Location of tumour
Upper (C) 8 (18) 6 (12) N.S.
Middle (M) 5 (11) 8 (15)
Lower (A) 31 (70) 37 (71)
4 Tumour size, cm (mean s.d.) 8.1±3.9 8.1±4.1 N.S.
5 Gross appearance
Superficial 6 (14) 2 (4) N.S.
Localised 18 (41) 16 (31)
Infiltrative 18 (41) 30 (58)
Unclassified 2 (4) 4 (7)
6 Histologic type
Papillary 0 (0) 2 (4) N.S.
Well 4 (9) 9 (17)
Moderately 14 (32) 15 (29)
Poorly 20 (45) 24 (46)
Signet 3 (7) 0 (0)
Mucinous 3 (7) 2 (4)
7 Mode of invasion
Expansive 9 (20) 6 (12) N.S.
Intermediate 17 (39) 23 (44)
Infiltrative 13 (30) 18 (35)
8 Depth of cancer invasionb
m, sm 6 (14) 5 (10) N.S.
pm, ss 11 (25) 14 (28)
se, si 27 (61) 33 (63)
9 Invasion into lymphatics
Negative 5 (11) 3 (6) N.S.
Positive 39 (89) 49 (94)
10 Metastases to the lymph nodes
Negative 16 (36) 8 (15) P<0.05
Positive 28 (84) 44 (85)
11 Venous invasion
Negative 14 (32) 6 (12) P<0.05
Positive 30 (68) 46 (88)
12 Metastasis to the liver
Negative 40 (91) 46 (88) N.S.
Positive 4 (9) 6 (12)
13 Peritoneal dissemination
Negative 40 (91) 46 (88) N.S.
Positive 4 (9) 6 (12)
Total 44 (100) 52 (100)
aNot significant; bDepth of invasion. m: musoca; sm: submucosa; pm: muscularis propria; ss: cancer cells extend to subserosa; se: cancercells present on the serosal surface and exposed to the peritoneal cavity; si: cancer cells infiltrating neighbouring tissue.592 Y. KAKEJI et al.
Table II p53 overexpression inprimary tumour and metastatic lymph
nodes
Primary tumour Metastatic lymph node
p53(-) 1 1 p53(-)
7
p53(+) 1 7 p53(+)
17 17
Table III p53 overexpression, DNA ploidy, and proliferative
activity
p53 staining
Negative Positive P value
DNA ploidy
Diploid 24 (55%) 16 (31%) P<0.05
Aneuploid 20 (45%) 36 (69%)
DNA index
(mean±s.d.) 1.19±0.26 1.30±0.28 P<0.05
Ki-67 labelling
percentage
(mean±s.d.) 25.1 ± 10.7% 30.6± 12.0% P<0.05
p53-positive cases is 1.30, a value significantly higher than
that (1.19) for the p53-negative cases (P<0.05).
The proliferative activity expressed by mean Ki-67 labell-
ing percent was 30.6% for p53-positive cases, a value signifi-
cantly higher than 25.1% for the p53-negative cases (P<
0.05).
Discussion
In the present immunohistochemical study of human gastric
cancer, we found that some diploid tumours or early stage
gastric cancers showed an overexpression of p53, hence the
possibility that mutation in this gene may occur, even in the
early stage of cancer progression has to be considered. This
notion is also supported by the finding that p53 mutations
were involved in the formation of both carcinomas and
adenomas which occur in familial polyposis coli (Shirasawa
et al., 1991).
Histologically, abnormal p53 protein expression was often
recognised in cancer cells in tubular or medullar formation
regardless of predominant histologic type. These findings are
in close agreement with the report of Yasui et al. (1991), in
which loss of heterozygosity on chromosome Sq and 17p was
frequent in cases of well differentiated types of gastric cancer.
The relationship between p53 overexpression and metasta-
tic spread to lymph nodes was noted in breast cancer
(Davidoff et al., 1991a). In our study, there was a significant
association between overexpression of p53 in gastric cancer
and lymph node metastasis. Tumours with positive p53 stain-
ing frequently metastasised to lymph nodes and most metas-
tatic lesions showed positive p53 staining. Furthermore,
tumours with positive p53 staining had a higher proliferative
activity than did those with which stained negatively. Catto-
retti et al. (1988) reported a correlation between p53
immunoreaction and the Ki-67 score in cases of breast
cancer. We also reported data that tumours with a high
proliferative activity often metastasised to lymph nodes
(Kakeji et al., 1991). There are findings that nuclear phos-
phoprotein p53 is expressed in all cells late in the GI phase of
the cycle and may regulate entry of the cells into the S phase
(DNA synthesis) (Shohat et al., 1987). Hence failure to
appropriately regulate p53 expression may lead to an uncon-
trolled cell growth. In light of all these observations, the
mutation of p53 seems to lead to activation of cell prolifera-
tion and the risk or lymph node metastasis is increased. The
over-expressed mutant p53 is not merely a remnant of the
mutational inactivation of p53 suppressor function, but also
actively promotes growth of the tumour. As shown in Table
II, positive staining for p53 occurred only in the lymph
nodes, in seven cases. As staining for p53 was positive in the
early stage gastric cancers and there was some heterogeneity
in this staining, the primary lesion may have contained a
subpopulation of the mutant p53.
As for prognosis and p53 stainability, Scott et al. (1991)
reported no difference in cases of colorectal carcinoma, how-
ever, Iwaya et al. (1991) did find differences in cases of breast
carcinoma. Though we found no significant difference
between p53 positive and negative tumours with regard to
2-year or 3-year survival rates, a longer follow-up is needed
before conclusions can be reached.
Considering the association between genetic change and
protein production, most of the cancers showing nuclear p53
immunoreaction also carried a mutation of the p53 gene, as
noted in studies of breast, colorectal and lung cancer cell
lines and tissues (Bartek et al., 1990; Rodrigues et al., 1990;
Iggo et al., 1990; Davidoff et al., 1991b). Though the number
was small, Seruca et al. (1992) reported the association and
some discrepancy between immunoreactivity and mutations
in gastric cancer. Immunohistochemical analysis of malignant
tissues appears to be a valid method which can be used to
screen for the presence of mutant p53, however, it does have
limitations. Data on the immunohistochemistry of p53 in
gastric cancer may be clinically useful for getting some in-
formation on the metastatic potential to lymph nodes.
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